Home » Clinical Trials » Solid tumors » NCT06084286
NCT06084286

A Phase I, Open-label, Single-arm, Dose-escalation and Expansion Study of Specific Dual-targeting CLDN18.2 and PD-L1 CAR-T for Patients with CLDN18.2-positive Advanced Solid Tumors

Study Summary

Claudin18.2(CLDN18.2) is a kind of integrin membrane protein in the tight junction between epithelium and endothelium, which is highly expressed in many solid tumors, especially in gastric cancer and pancreatic cancer. The CLDN18.2/PD-L1 dual-targeting CAR-T will be investigated in patients with CLDN18.2-positive advance solid tumors.

Want to learn more about this trial?

Request More Info

Interventions

Dual-targeting CLDN18.2 and PD-L1 CAR-T cellsBIOLOGICAL
The trial consists of a traditional '3 + 3' pattern dose-escalation phase and a dose-expansion phase.

Study Locations

FacilityCityStateCountry
West China Hospital, Sichuan UniversityChengduSichuanChina

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026